Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Sells $12,073.23 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) EVP Anhco Nguyen sold 1,821 shares of the stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $6.63, for a total transaction of $12,073.23. Following the completion of the transaction, the executive vice president now owns 34,118 shares of the company’s stock, valued at approximately $226,202.34. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Atara Biotherapeutics Stock Down 0.1 %

Shares of NASDAQ:ATRA opened at $7.18 on Wednesday. The firm has a fifty day moving average of $9.20 and a two-hundred day moving average of $14.52. The firm has a market capitalization of $34.59 million, a P/E ratio of -0.13 and a beta of 0.52. Atara Biotherapeutics, Inc. has a 12-month low of $4.96 and a 12-month high of $49.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The business had revenue of $28.64 million for the quarter, compared to the consensus estimate of $48.30 million. Equities research analysts expect that Atara Biotherapeutics, Inc. will post -15.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 22nd. Canaccord Genuity Group restated a “buy” rating and issued a $13.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday, June 26th. They issued a “hold” rating on the stock. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price target for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. Finally, The Goldman Sachs Group decreased their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research report on Wednesday, July 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $185.50.

Institutional Investors Weigh In On Atara Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Vontobel Holding Ltd. acquired a new stake in shares of Atara Biotherapeutics in the 4th quarter valued at $41,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at $79,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at $53,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after purchasing an additional 4,903,159 shares during the last quarter. Finally, Redmile Group LLC lifted its stake in shares of Atara Biotherapeutics by 1.7% in the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after purchasing an additional 156,863 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.